Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

NCT06504901 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Tislelizumab
DRUG: Interleukin-2
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Neupogen

Sponsor

The First Affiliated Hospital with Nanjing Medical University